熱門資訊> 正文

Terns Pharmaceuticals GAAP每股收益为-0.27美元

2025-11-11 05:55

Terns Pharmaceuticals press release (TERN): Q3 GAAP EPS of -$0.27.
As of September 30, 2025, cash, cash equivalents and marketable securities were $295.6 million, as compared with $358.2 million as of December 31, 2024. Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2028

More on Terns Pharmaceuticals

Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Terns Pharmaceuticals: Valued As If It Can't Win
Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints
Seeking Alpha’s Quant Rating on Terns Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。